41L.F Laboratorios Farmaceuticos Rovi S.A

Healthcare Biotechnology Frankfurt Exchange
69.90 EUR
Close of Nov 12, 2026
53.10 84.19
Market cap
EUR 3.57B
P/E
17.5x
P/B
4.56x
ROE
24.1%
Dividend yield
1.34%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 41L.F undervalued?

Graham number
Price69.90
Graham value37.14
Premium88.2%

41L.F trades 88.2% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Laboratorios Farmaceuticos Rovi S.A fundamental analysis

No fundamental analysis for Laboratorios Farmaceuticos Rovi S.A yet.

Laboratorios Farmaceuticos Rovi S.A stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Laboratorios Farmaceuticos Rovi S.A

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, …

Full company profile